News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 37–72
- Matches
- 82
- Sources here
- 21
- Companies here
- 9
Search results
Stored financial headlines
Active search
82 matching headlines
Ticker or company: AMADMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) will release its financial results for the second quarter and first half ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The company will host a conference call on the same day at 8:30 …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada Ltd. (NASDAQ: KMDA) sets August 12 call on Q2 2026
Kamada Ltd. (NASDAQ: KMDA) announced it will release its financial results for the second quarter and first half ended June 30, 2026, before the U.S. market opens on Wednesday, August 12, 2026. The biopharmaceutical company will host an investment community conference call at 8:30 …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Amadeus IT Group SA (AMADF) (H1 2026) Earnings Call Highlights: Resilient Growth Amid Middle East Headwinds
This article first appeared on GuruFocus. Revenue: EUR3,335 million, representing 5% constant currency growth and 2% reported growth. Adjusted EBIT: EUR1,012 million, up 5% at constant currency and 4% reported. Adjusted Diluted EPS: Increased 7% at constant currency. Diluted EPS: EUR1.64, representing 1% growth. …
AI3A
main company
Sharemaestro market context
Trend signal started
52 weeks -21.3%
Price to book forward of Kamada Ltd. – NASDAQ:KMDA
This page provides financial information for Kamada Ltd. (NASDAQ: KMDA), specifically focusing on its "Price to book forward" metric. The content highlights that the market was closed at the time of viewing and indicates no trades occurred. It is a financial data page from …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%Amadeus IT Group SA (AMADF) (H1 2026) Earnings Call Highlights: Resilient Growth Amid Middle ...
This article first appeared on GuruFocus. Revenue: EUR3,335 million, representing 5% constant currency growth and 2% reported growth. Adjusted EBIT: EUR1,012 million, up 5% at constant currency and 4% reported. Adjusted Diluted EPS: Increased 7% at constant currency. Diluted EPS: EUR1.64, representing 1% growth. …
Sharemaestro market context Price below Trend Line 52 weeks -37.7% · Next-week setup negative 14.4%Kamada Ltd (KMDA) Financial Health: Profitability & Balance Sheet Analysis
Kamada Ltd (KMDA) has a stable financial score of 7.95, ranking 90th in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 2.78% year-over-year increase in quarterly revenue to $45.24 million and a 4.24% rise in net profit. However, specific detailed …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%KMDA|Kamada Ltd|Price:7.070|Chg%:+0.080
This article provides a detailed stock analysis for Kamada Ltd (KMDA), highlighting its current market trends, financial performance, and analyst ratings. Based on three analysts, the stock has a "Buy" rating with a target price of $13.00, representing an 84.14% upside. While Kamada Ltd …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada Ltd (KMDA) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on Kamada Ltd's (KMDA) dividend and stock split history. It notes that the company has not distributed any dividends over the past five years. The page displays current stock information such as price, market cap, and P/E ratio, while also …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%Kamada Ltd (KMDA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Kamada Ltd (KMDA) shareholder structure, including major individual and institutional investors. It lists the top shareholders and their proportionate holdings, categorizes shareholders by type (e.g., Private Equity, Investment Advisor), and tracks institutional shareholding over several quarters. Key …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada Ltd (KMDA) Cash Flow
This article provides a detailed cash flow statement for Kamada Ltd (KMDA), covering quarterly and annual data for operating, investing, and financing activities. It includes breakdowns of various cash flow components, year-over-year percentage changes, and specific monetary figures. The content aims to help users …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada Ltd. Revenue Breakdown – NASDAQ:KMDA
Kamada Ltd. (NASDAQ: KMDA) reported a total revenue of $180.46 million USD last year. The majority of this revenue, $169.09 million USD, came from its Proprietary Products segment, an increase from $143.70 million USD in the previous year. The United States was the largest …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%Kamada Ltd. (KMDA) Stock Analysis: Exploring an 86.78% Potential Upside in the Healthcare Sector
Kamada Ltd. (NASDAQ: KMDA) shows significant potential upside of 86.78%, trading at $6.96 with an average analyst target of $13.00. The company, specializing in plasma-derived protein therapeutics, boasts a diverse product portfolio and a 3.60% dividend yield. Despite mixed technical indicators, analyst sentiment is …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada stock trades steadily as plasma-derived therapies support revenue growth
Kamada Ltd. (ISIN IL0010952647) is an Israeli biopharmaceutical company focused on plasma-derived and specialty therapies for rare and serious conditions. The company's revenue of approximately $100 million annually is driven by sales of plasma-derived products and contract manufacturing, providing a stable income stream. Kamada's …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%Kamada Signs $50 Million Plasma Supply Agreement With Biopharmaceutical Firm
Kamada (TASE: KMDA; NASDAQ: GMDA) has signed a new five-year plasma supply agreement with a leading biopharmaceutical firm for up to $50 million, replacing previous agreements for plasma supply and services. This agreement is expected to significantly increase Kamada's access to plasma, boost its …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada jumps on $50m source plasma deal
Kamada (Nasdaq: KMDA; TASE: KMDA) has announced a new three-year agreement to supply normal source plasma to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue. This deal validates Kamada's investment in its US-based plasma collection centers and supports its vertical-integration …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada’s centers plan ~50,000 liters of plasma each at full capacity
Kamada (NASDAQ: KMDA) announced a new three-year agreement to supply normal source plasma, expected to generate approximately $50 million in revenue. This plasma will come from its FDA-approved collection centers in Houston and San Antonio, Texas, each designed for a planned capacity of about …
Sharemaestro market context Price below Trend Line 52 weeks -6.4%Kamada Ltd. (NASDAQ: KMDA) signs three-year $50M plasma supply agreement
Kamada Ltd. announced a new three-year agreement to supply normal source plasma, expected to generate approximately $50 million in revenue. The plasma will be sourced from its FDA-approved collection centers in Texas, with initial commercial sales planned for Q4 2026. This agreement supports Kamada's …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) has announced a new three-year, $50 million sales agreement to supply normal source plasma to a leading biopharmaceutical company specializing in plasma-derived therapies. The agreement leverages Kamada's FDA-approved plasma collection centers in Texas, with initial commercial sales anticipated …
KMDA
main company
Sharemaestro market context
Price below Trend Line
52 weeks +8.8%